Kringle advances HGF therapy for renal failure
This article was originally published in Scrip
Executive Summary
The Japanese bioventure Kringle Pharma has filed a US IND to begin clinical trials with a recombinant hepatocyte growth factor for the treatment of acute renal failure (ARF). The disorder, which is associated with a range of conditions including shock, has a mortality rate of around 50% and is now treated only symptomatically, Kringle notes. HGF is under-expressed in the condition, which affects around 700,000 people in the US, and studies suggest that administration of additional quantities aids the regeneration of renal function, the Osaka-based firm said. It has already partnered with the Swedish company Tripep to develop HGF for chronic leg wounds.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.